Bellicum Pharmaceuticals, Inc. (BLCM) |
|
1.21 -0.01 (-0.82%)
|
06-26 19:55 |
|
Open: |
1.2 |
Pre. Close: |
1.22 |
|
High:
|
1.25 |
Low:
|
1.2 |
|
Volume:
|
7,956 |
Market Cap:
|
10(M) |
|
|
|
|
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.25 - 1.26 |
1.26 - 1.26 |
|
Low:
|
1.18 - 1.19 |
1.19 - 1.2 |
|
Close:
|
1.2 - 1.21 |
1.21 - 1.22 |
|
Technical analysis |
as of: 2022-06-24 4:38:26 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, downgraded from strong buy. Upward movement continues, but could change at any time. |
| Target: |
Six months: 1.52 One year: 1.75 |
| Support: |
Support1: 1 Support2: 0.83 |
| Resistance: |
Resistance1: 1.3 Resistance2: 1.5 |
| Pivot: |
1.14  |
| Moving Average: |
MA(5): 1.12 MA(20): 1.2
MA(100): 1.59 MA(250): 2.05 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 46 %D(3): 28 |
| RSI: |
RSI(14): 47.4 |
| 52-week: |
High: 4.03 Low: 1 |
| Average Vol(K): |
3-Month: 27 (K) 10-Days: 22 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BLCM ] has closed below upper band by 25.3%. Bollinger Bands are 40.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Wed, 22 Jun 2022
StockNews.com Initiates Coverage on Bellicum Pharmaceuticals (NASDAQ:BLCM) - Defense World
Tue, 14 Jun 2022
Bellicum Pharmaceuticals (NASDAQ:BLCM) Coverage Initiated by Analysts at StockNews.com - Defense World
Wed, 08 Jun 2022
Reading and writing habits compensate for aging effects in speech connectedness | npj Science of Learning - Nature.com
Tue, 07 Jun 2022
Where Does Bellicum Pharmaceuticals Inc (BLCM) Stock Fall in the Biotechnology Field After It Is Down -29.08% This Week? - InvestorsObserver
Thu, 24 Mar 2022
Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update - GlobeNewswire
Wed, 26 Jan 2022
Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conference - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
8 (M) |
| Shares Float |
7 (M) |
|
% Held by Insiders
|
1.6 (%) |
|
% Held by Institutions
|
30.3 (%) |
|
Shares Short
|
200 (K) |
|
Shares Short P.Month
|
233 (K) |
Stock Financials |
|
EPS
|
0.68 |
|
EPS Est Next Qtl
|
-0.75 |
|
EPS Est This Year
|
-3.02 |
|
EPS Est Next Year
|
-2.96 |
|
Book Value (p.s.)
|
-1.46 |
|
Profit Margin (%)
|
-156.6 |
|
Operating Margin (%)
|
-393.4 |
|
Return on Assets (ttm)
|
-34 |
|
Return on Equity (ttm)
|
-33.5 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-2.07 |
|
Sales Per Share
|
0.73 |
|
EBITDA (p.s.)
|
-2.9 |
|
Qtrly Earnings Growth
|
-93.4 |
|
Operating Cash Flow
|
-23 (M) |
|
Levered Free Cash Flow
|
-28 (M) |
Stock Valuations |
|
PE Ratio
|
1.76 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-0.84 |
|
Price to Sales
|
1.63 |
|
Price to Cash Flow
|
-0.44 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2020-02-05 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
